One popular health platforms is promoting GLP-1 microdosing for weight loss: But how safe and effective is this approach?

Next-generation weight-loss pills could hit the market in the coming months, with new data raising a key question: Will ...

Eli Lilly's experimental GLP-1 pill shows promise in a Phase Three trial, helping users lose an average of 12% of body weight, potentially transforming diabetes and obesity treatment.

The agency shared information from reports by users of compounded semaglutide and tirzepatide who have experienced health issues.

GLP-1 receptor agonists like semaglutide and the dual GIP/GLP-1 agonist tirzepatide mimic naturally occurring hormones that regulate blood sugar, appetite, and digestion. GLP-1 (glucagon-like ...

In the first Phase 3 trial of its once-daily oral GLP-1 pill in people with obesity, drugmaker Eli Lilly said Thursday that ...

A Cell Metabolism study reveals that GIPR signaling in oligodendrocytes enhances brain access and weight-loss efficacy of GLP ...

Drugmaker Eli Lilly says after successful results in a phase 3 clinical trial, it expects to submit a GLP-1 weight loss pill ...

Doctors advise most patients on GLP-1 obesity drugs such as Wegovy and Zepbound to stay on them to keep the weight off, but ...

GLP-1 medications have an impressive history of weight loss, but there are options to consider. For example, one study on the oral medication Qsymia found people lost up to 11% of their body ...

A new study in mice has found that muscle loss associated with weight loss from GLP-1 medications like Ozempic may not be as ...

As other pharmas drop next-gen obesity assets, Eli Lilly’s experimental oral GLP-1 has prompted weight loss up to ...